There are 142 resources available
47P - Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy (former platinum-resistant).
Presenter: David Illescas
Session: Poster Display session
48P - Response to chemotherapy following PARP inhibition in ovarian cancer (OC) patients at Mount Vernon Cancer Centre
Presenter: Alison Berner
Session: Poster Display session
49P - First Report on Pan-Immune-Inflammation Value as a New Prognostic Factor in Ovarian Cancer: A Biomarker Analysis of OVANORDEST-1 Study
Presenter: Khalid EL BAIRI
Session: Poster Display session
50P - Can We Learn From Failures? A Systematic Review and Metanalysis of Phase III Trials in Platinum Resistant Ovarian Cancer
Presenter: Federica Martorana
Session: Poster Display session
51P - Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations.
Presenter: Roberto Buonaiuto
Session: Poster Display session
52P - Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group
Presenter: Lucia Musacchio
Session: Poster Display session
53P - Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
Presenter: Alberto Farolfi
Session: Poster Display session
54P - Fallopian tube cancer and ovarian cancer: A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape
Presenter: Abdallah Allam
Session: Poster Display session
55P - Evolution of Genetic Testing after Ovarian Cancer (OC) diagnosis
Presenter: Ana Teresa Lopes Bruno
Session: Poster Display session
56P - Differential response to DNA damaging agents of patients carrying the germline BRCA1 c.211 A>G pathogenic variant
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display session